Overview

Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain

Status:
Completed
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
Phase:
Phase 1
Details
Lead Sponsor:
Sorrento Therapeutics, Inc.
Collaborator:
Scintilla Pharmaceuticals, Inc.